Agenda

Monday, February 22, 2010

9:00 a.m. - 6:00 p.m.     
Pharma Partnering Session
For Pharma and Emerging Biotech Companies Only
>> Click here for more information (Pre-registration Required)

10:00 a.m. - 1:00 p.m. 
Venture Day with Hoffman-La Roche Inc.   
By Invitation Only (Pre-registration Required)
>> Click here for more information (Pre-registration Required)

11:45 a.m. - 1:00 p.m.     
Joint Board Lunch for CED, NCBIO and North Carolina Biotechnology Center    
By Invitation only

12:30 p.m. – 6:45 p.m.    
Registration Open    
For all conference attendees

1:30 p.m. - 3:00 p.m.    
Opening Remarks and Featured Speakers  

• The Honorable Beverly Eaves Perdue, Governor of North Carolina (Remarks via Video)
• Ernest Mario, Ph.D., Chairman and CEO, Capnia
  Partnering in Biotech and Pharma. Ernie Mario will discuss the good, the bad and the ugly; complexities; real life examples; traps to avoid; and the effect on value.
• Steve Krognes, Senior Vice President and CFO, Genentech, Inc.
  Roche & Genentech: Taking the Partnership to a New Level. Steve Krognes will give a bit of background on the historical relationship, ownership and collaboration between Roche and Genentech, starting in 1990. How it developed into the most successful Pharma & Biotech partnership in the industry, why Roche decided to change such a successful model; describe the deal, transaction phase, negotiations and the final outcome; and finally some observations on the Integration and how that has worked to date.

3:00 p.m. - 3:30 p.m.    
Break

3:30 p.m. – 4:45 p.m.    
Featured Panel Session:    
Impact of Healthcare Reforms on Biotech
While there is still significant uncertainty regarding the policies and impact of US healthcare reforms, the general direction is clear: accessibility and affordability are the key elements the new administration, and subsequently for the biotech industry, how it will continue to foster the USA’s current high level of biotech innovation. This featured panel will focus on the impact and implementation of the current healthcare reforms on the biotech and pharmaceutical industries, while discussing potential strategies for companies to innovate and grow during a time of dramatic change.

Panelists:

• Stephen Stefano, Author of Passion and ICE, former SVP, GlaxoSmithKline (Moderator)
• Lanier M. Cansler, Secretary, North Carolina Department of Health and Human Services
• Kevin Schulman, Associate Director of The Duke Clinical Research Institute; Professor of Medicine, Duke University Medical Center; Professor of Business Administration, Fuqua School of Business
• Anthony Y. Sun, Partner, Aisling Capital
• J. Bradley Wilson, President and CEO, Blue Cross and Blue Shield of North Carolina

4:45 p.m. – 5:15 p.m.     
Break

5:15 p.m. – 6:30 p.m.     
Featured Panel Session:
Financing Innovation: Where is the Funding Model Headed in Biotechnology?
There is more than one way to fund new companies: In this challenging environment, CEOs and entrepreneurs must consider a variety of different sources of capital to fund discovery and early development. This featured panel will look at the role of venture capital, federal funding options, public markets, as well as the increasingly important role of corporate venture arms and examine how companies should position themselves to take advantage of these sources of capital.

Panelists (partial list):

• Stephen Sands, Vice Chairman, US Investment Banking and Global Co-Head, Lazard's Healthcare Group (Moderator)
• John Clerici, Partner and Chair, Life Sciences and Public Health Preparedness Practice, McKenna Long & Aldridge LLP
• Cecilia Gonzalo, Managing Director, Warburg Pincus LLC
• Ed Mathers, Partner, NEA
• Lauren Silverman, Managing Director, Novartis Option Fund
• Lawrence (“Larry”) D. Stern, Chairman and CEO, Talecris Biotherapeutics

6:30 p.m. – 8:00 p.m.     
Gala Reception

Tuesday, February 23, 2010

7:30 a.m. – 1:00 p.m.     
Registration Open       

7:30 a.m. – 9:00 a.m.    
Continental Breakfast    
For all conference attendees

7:30 a.m. - 8:30 a.m.    
CEO Breakfast    
By Invitation Only

• Louis G. Lange, M.D., Ph.D., General Partner, Asset Management (former Chairman, CEO and CSO, CV Therapeutics, Inc.)

8:45 a.m. - 9:45 a.m.    
Opening Remarks and Featured Speakers    

• Louis G. Lange, M.D., Ph.D., General Partner, Asset Management (former Chairman, CEO and CSO, CV Therapeutics, Inc.)
• The Honorable Billy Tauzin, President and CEO, Pharmaceuticals Research and Manufacturers of America (PhRMA)

9:45 a.m. – 10:15 a.m.
Break   

10:15 a.m. – 11:30 a.m.
Featured Panel Session:
CEO Panel: Leadership in Changing Times
Despite a very challenging environment over the past year, these CEOs of both private and public companies have been successful in raising significant capital, establishing new corporate partnerships and creating new market opportunities despite the turbulent times. This featured panel of Biotech CEOs will discuss the leadership issues that are most important during the current economic situation and provide several case studies. Panelists will discuss how to maintain composure, keep teams motivated and cohesive, and establish creative ways to get things done with fewer resources. They will discuss the importance of thinking strategically when circumstances often force tactical solutions.

Panelists:

• Christy Shaffer, Ph.D., President and CEO, Inspire Pharmaceuticals (Moderator)
• J. Donald deBethizy, Ph.D., President and CEO, Targacept, Inc.
• Neal Fowler, CEO, Liquidia Technologies, Inc.
• Michael Pearson, Chairman & CEO, Valeant Pharmaceuticals International
• Jon Stonehouse, President & CEO, Biocryst Pharmaceuticals, Inc.

11:30 a.m. - 11:45 a.m.
Break     

11:45 a.m. – 1:00 p.m.
Featured Panel Session:
Personalized Medicine: Opportunities and Challenges
Personalized Medicine refers to the tailoring of medical treatment to each patient. It is a key approach to optimizing patient healthcare delivery through a more complete understanding of the patient's disease and response to interventions. This panel will discuss how personalized medicine is employed in the clinic today. What value does it have to patients? How is personalized medicine being adopted in the context of today’s healthcare and reimbursement systems? What are the opportunities and challenges to accelerate adoption?

Panelists (partial list) :

• Michael Stocum, Managing Director, Personalized Medicine Partners, LLC (Moderator)
• Patrick F. Terry, Co-Founder, Genomic Health
• Linda Harpole, VP, Global Health Outcomes, GlaxoSmithKline
• Louis I. Hochheiser, M.D., Medical Director, Clinical Policy Development, Humana
• Michael Rosenberg, CEO, Health Decisions, Inc.

1:00 p.m. - 2:30 p.m.
Featured Lunch Speaker and CED Biotechnology Leadership Award

• Award Recipient: Randall Marcuson, former President and CEO of Embrex, Inc. (acquired by Pfizer Animal Health)
• Featured Speaker: Allen D. Roses, MD, FRCP, Jefferson-Pilot Professor of Neurobiology and Neurology; Director, Deane Drug Discovery Institute; Senior Scholar, Fuqua School of Business
  "The Blue Wine Group: An Experiment in Industry Academic Synergies"
  Dr. Allen Roses will discuss the research conducted at The Deane Drug Discovery Institute at Duke and along with his three independent companies, Cabernet, Zinfandel and Shiraz Pharmaceuticals, Inc. that are designed to accomplish translational medicine with a laser-like focus.

2:30 p.m. – 2:45 p.m.      
Break
   
2:45 p.m. – 4:00 p.m.    
Concurrent Panel Discussion    
Opportunities and Challenges in Global Health

Panelists:

• Nicole Fouché, Executive Director, Triangle Global Health Consortium (Moderator)
• Oren J. Cohen, M.D., Chief Medical and Scientific Officer, Quintiles Transnational Corp.
• E. Wayne Holden, Executive VP, Social, Statistical, & Environmental Sciences (SSES), RTI International
• Robert E. Johnston, PhD., Professor, Immunology and Microbiology, Lineberger Comprehensive Cancer Center; Director, Carolina Vaccine Institute, UNC- School of Medicine; Executive Director, Global Vaccines, Inc.
• Wayne Myers, Director, Public Health Informatics, SRA International, Inc.
• Jon Stonehouse, CEO, Biocryst Pharmaceuticals

2:45 p.m. – 4:00 p.m.
Concurrent Panel Discussion
Getting the Deal Done: Licensing Best Practices for Emerging Companies
Join this panel of business development executives for an interactive discussion on successful strategies for emerging companies in gaining the attention of potential in-licensors. Panelists will address the following questions: What therapeutic areas are most attractive to large pharmaceutical and biotech companies? At what stage of development do these types of companies typically look to do the deal? How do large pharmaceutical and biotech companies prefer to see deals structured? How do you best value and position your asset to a potential partner? What common licensing missteps do emerging companies often make when pursuing a partner?

Panelists (partial list):

• Jon McGarity, Executive Vice President, Marketing, Campbell Alliance (Moderator)
• Jeffrey Brennan, Vice President, Business and Commercial Development, Targacept, Inc.
• David Donabedian, Ph.D., M.B.A., Vice President of Strategic Alliances, U.S. ceedd, GlaxoSmithKline
• Mark A. Miller, Vice President of Corporate Business Development, Eli Lilly and Company
• Steve Rushton, Senior Business Development Director, Neuroscience, Astrazeneca
• Bob Silverman, Global Licensing Director, Hoffmann-La Roche, Inc.